Kemwell Biopharma

kemwellbiopharma.com

Kemwell is a contract biologics development and CMO company providing services to global biopharmaceutical organizations. Kemwell facilities, located in Bangalore, India, are designed and developed with technological support from a leading German pharma company. Kemwell provides customers with cost-effective access to state-of-the-art technology for all mammalian cell culture based products’ development and manufacturing. 15,000 sq. m. Kemwell facility consists of a cGMP drug substance manufacturing area with over 4000L bioreactor capacity, sterile fill and finish areas for cGMP drug product manufacturing and process development laboratories to support production of protein therapeutics from mammalian-cell culture – monoclonal antibodies, bi-specific antibodies, fusion proteins, etc. Kemwell is capable of supporting novel, bio-better and biosimilar programs’ preclinical development, clinical development, cGMP clinical manufacturing and cGMP commercial manufacturing.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CONCERTAI NAMES CLAUDIO D'AMBROSIO, PHD, AS HEAD OF BIOPHARMA PARTNERSHIPS AND RWE SOLUTIONS

Prnewswire | September 10, 2020

news image

ConcertAI has hired Claudio D'Ambrosio, PhD, as head of biopharma partnerships and real-world evidence Solutions. Claudio brings over 15 years of experience as a cancer researcher, commercial leader, and strategic scientific partner to the life sciences industry to help advance the goals of ConcertAI of bringing rapid innovation and precision real-world evidence oncology to the world's top global pharmaceutical companies. ConcertAI is a fast-growing company with the leading technology fo...

Read More

PHARMA TECH

CPHI PARTNERS WITH INFORMA PHARMA INTELLIGENCE TO PRESENT THE 2021 HYBRID EDITION OF CPHI - P-MEC EXPO IN THE NATIONAL CAPITAL REGION ( NCR)

Informa Pharma Intelligence | November 26, 2021

news image

Informa Pharma Intelligence, one of the leading business intelligence providers and knowledge partners, is pleased to announce the 2021 hybrid edition of CPhI – P-MEC conducted by CPhI Conference. The Online Conference & Networking is being held between 15th to 30th Nov 2021, while the In-Person event is being held between 24th to 26th Nov 2021 at India Expo Centre– Greater Noida, Delhi. In a bid to stay afloat towards increasing contemporary demand towards high qu...

Read More

PHARMA TECH

KIOMED PHARMA AND HANSOH PHARMA ANNOUNCE LICENSE AGREEMENT FOR KIOMEDINEVSONE IN CHINA’S MAINLAND, MACAU AND TAIWAN

KiOmed Pharma and Hansoh Pharma | September 27, 2022

news image

KiOmed Pharma, a Belgian biotechnology company with a focus on the development, manufacture and distribution of safe and effective medical devices based on a medical-grade highly pure natural chitosan-derivative, and Hansoh Pharmaceutical Group Company Limited a leading biopharmaceutical company in Asia, today announced a license agreement for the development and commercialization of KiOmedinevsOne, a carboxymethyl chitosan injection that has been launched in Europe for the treatment of knee ost...

Read More

BUSINESS INSIGHTS

VIFOR PHARMA DRIVES TRANSFORMATION WITH DIVESTMENT OF NON-CORE FINISHED DRUG MANUFACTURING TO CORDENPHARMA

Vifor Pharma Group | December 17, 2021

news image

Vifor Pharma Group announced the divestment of its finished drug product manufacturing business to CordenPharma, a full-service Contract Development & Manufacturing Organization of APIs, Excipients, Drug Products, and associated Packaging services. This decision reinforces Vifor Pharma’s strategy to transform the company into a multi-brand commercial organization, focusing on its core capabilities in-licensing, partnering and commercializing products in nephrology, and to further grow ...

Read More
news image

CONCERTAI NAMES CLAUDIO D'AMBROSIO, PHD, AS HEAD OF BIOPHARMA PARTNERSHIPS AND RWE SOLUTIONS

Prnewswire | September 10, 2020

ConcertAI has hired Claudio D'Ambrosio, PhD, as head of biopharma partnerships and real-world evidence Solutions. Claudio brings over 15 years of experience as a cancer researcher, commercial leader, and strategic scientific partner to the life sciences industry to help advance the goals of ConcertAI of bringing rapid innovation and precision real-world evidence oncology to the world's top global pharmaceutical companies. ConcertAI is a fast-growing company with the leading technology fo...

Read More
news image

PHARMA TECH

CPHI PARTNERS WITH INFORMA PHARMA INTELLIGENCE TO PRESENT THE 2021 HYBRID EDITION OF CPHI - P-MEC EXPO IN THE NATIONAL CAPITAL REGION ( NCR)

Informa Pharma Intelligence | November 26, 2021

Informa Pharma Intelligence, one of the leading business intelligence providers and knowledge partners, is pleased to announce the 2021 hybrid edition of CPhI – P-MEC conducted by CPhI Conference. The Online Conference & Networking is being held between 15th to 30th Nov 2021, while the In-Person event is being held between 24th to 26th Nov 2021 at India Expo Centre– Greater Noida, Delhi. In a bid to stay afloat towards increasing contemporary demand towards high qu...

Read More
news image

PHARMA TECH

KIOMED PHARMA AND HANSOH PHARMA ANNOUNCE LICENSE AGREEMENT FOR KIOMEDINEVSONE IN CHINA’S MAINLAND, MACAU AND TAIWAN

KiOmed Pharma and Hansoh Pharma | September 27, 2022

KiOmed Pharma, a Belgian biotechnology company with a focus on the development, manufacture and distribution of safe and effective medical devices based on a medical-grade highly pure natural chitosan-derivative, and Hansoh Pharmaceutical Group Company Limited a leading biopharmaceutical company in Asia, today announced a license agreement for the development and commercialization of KiOmedinevsOne, a carboxymethyl chitosan injection that has been launched in Europe for the treatment of knee ost...

Read More
news image

BUSINESS INSIGHTS

VIFOR PHARMA DRIVES TRANSFORMATION WITH DIVESTMENT OF NON-CORE FINISHED DRUG MANUFACTURING TO CORDENPHARMA

Vifor Pharma Group | December 17, 2021

Vifor Pharma Group announced the divestment of its finished drug product manufacturing business to CordenPharma, a full-service Contract Development & Manufacturing Organization of APIs, Excipients, Drug Products, and associated Packaging services. This decision reinforces Vifor Pharma’s strategy to transform the company into a multi-brand commercial organization, focusing on its core capabilities in-licensing, partnering and commercializing products in nephrology, and to further grow ...

Read More